Lyell Immunopharma, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Lyell Immunopharma, Inc. (LYEL) reported Net Income (Loss) Available to Common Stockholders, Basic of -$183.12 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-02-28
- Lyell Immunopharma, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$83.71M.
- Lyell Immunopharma, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$48.88M.
- Lyell Immunopharma, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was -$62.59M.
- Lyell Immunopharma, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was -$38.86M.
- Lyell Immunopharma, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$183.12M.
- Lyell Immunopharma, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$250.22M.
- Lyell Immunopharma, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$208.05M.
- Lyell Immunopharma, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was -$130.52M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$183.12M 10-K · filed 2023-02-28 | |||
| 2021-12-31 | -$83.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$132.58M derived: sum of 2 quarters · filed 2023-02-28 | -$195.18M derived: sum of 3 quarters · filed 2023-02-28 | -$250.22M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$48.88M 10-Q · filed 2021-11-12 | -$111.47M derived: sum of 2 quarters · filed 2021-11-12 | -$166.51M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$62.59M 10-Q · filed 2021-08-12 | -$117.64M 10-Q · filed 2021-08-12 | ||
| 2020-12-31 | -$38.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$74.58M derived: sum of 2 quarters · filed 2023-02-28 | -$175.23M derived: sum of 3 quarters · filed 2023-02-28 | -$208.05M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$35.72M 10-Q · filed 2021-11-12 | -$136.38M derived: sum of 2 quarters · filed 2021-11-12 | -$169.20M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$100.66M 10-Q · filed 2021-08-12 | -$133.48M 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | -$130.52M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |